About: Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
Creator	Aghakouchakzadeh, Maryam Dunn, Steven Geraiely, Babak Hajhossein Talasaz, Azita Kakavand, Hessam Sadeghipour, Parham Van Tassell, Benjamin
source	Medline; PMC
abstract	Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared “pandemic” by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1007/s10557-020-07037-2
bibo:pmid	32671601
has license	no-cc
sha1sum (hex)	0912f534628af93bc1d31f22d08f7836883f942a
schema:url	https://doi.org/10.1007/s10557-020-07037-2
resource representing a document's title	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
has PubMed Central identifier	PMC7360896
has PubMed identifier	32671601
schema:publication	Cardiovasc Drugs Ther
resource representing a document's body	covid:0912f534628af93bc1d31f22d08f7836883f942a#body_text
is schema:about of	named entity 'disease' named entity 'patients' named entity 'Patients' named entity 'GLOBALLY' named entity 'dexamethasone' named entity 'This' named entity 'infection' named entity 'infection' named entity 'declared' named entity 'World Health Organization' named entity 'SARS-CoV-2' named entity 'morbidity' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'pharmacotherapies' named entity 'COVID' named entity 'COVID' named entity 'COVID-19' named entity 'Cardiovascular Complications' named entity 'COVID-19' named entity 'fluid therapy' named entity 'Coronaviridae' named entity 'flecainide' named entity 'Protease inhibitors' named entity 'aPTT' named entity 'CYP450' named entity 'cardiovascular' named entity 'glucuronidation' named entity 'apixaban' named entity 'loop diuretics' named entity 'protease inhibitors' named entity 'critically ill patients' named entity 'COVID-19' named entity 'lopinavir/ritonavir' named entity 'supply-and-demand' named entity 'cardiovascular disorders' named entity 'myocardial injury' named entity 'coagulopathy' named entity 'drug-drug interactions' named entity 'peptide' named entity 'pharmacotherapy' named entity 'COVID' named entity 'cardiac diseases' named entity 'cardiovascular complications' named entity 'fibrinolytics' named entity 'metoprolol succinate' named entity 'monitoring of the heart' named entity 'QTc' named entity 'immune status' named entity 'beta-blockers' named entity 'ARDS' named entity 'antiviral agent' named entity 'COVID' named entity 'ECGs' named entity 'fibrin' named entity 'acute respiratory distress syndrome' named entity 'RAAS' named entity 'thyroid function' named entity 'fulminant' named entity 'VTE' named entity 'TNF-α' named entity 'COVID' named entity 'COVID' named entity 'metabolized' named entity 'D-dimer' named entity 'blood pressure' named entity 'RNA virus' named entity 'tocilizumab' named entity 'IL-6' named entity 'hydroxychloroquine' named entity 'dexamethasone' named entity 'COVID' named entity 'lopinavir/ritonavir' named entity 'sarilumab' named entity 'World Health Organization'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software